Neurological improvement in patients with chronic spinal cord injury treated with leuprolide acetate, an agonist of GnRH

Acta Neurobiol Exp (Wars). 2018;78(4):352-357.

Abstract

It has been reported that gonadotropin‑releasing hormone (GnRH), and its analogue leuprolide acetate (LA), have neurotrophic properties; particularly in the regeneration of injured spinal cord in animal models and in the case of a patient with spinal cord injury (SCI). The aim of this study was to establish whether treatment with LA improves sensitivity, motor activity and independence in patients with chronic SCI. Patients were treated LA once a month for six months. They were evaluated at the beginning and at the end of treatment; using a sensitivity and motor impairment scale, according to the American Spinal Injury Association (ASIA), and grade of independence scale; employing the spinal cord independence measure (SCIM). Statistical analysis showed a significant improvement in the ASIA sensory score and the SCIM score when comparing the initial versus final evaluation after six months of LA administration. Some patients showed an increase in frequency of bowel movements. Treatment with LA induces improvements in sensitivity, motor activity and independence in patients with chronic SCI. One advantage of this protocol is that it is a non-invasive method of easy and safe application, with few side effects.

MeSH terms

  • Adolescent
  • Adult
  • Chronic Disease
  • Female
  • Gonadotropin-Releasing Hormone / biosynthesis
  • Gonadotropin-Releasing Hormone / drug effects*
  • Humans
  • Leuprolide / pharmacology*
  • Male
  • Middle Aged
  • Recovery of Function / drug effects*
  • Spinal Cord Injuries / drug therapy*
  • Treatment Outcome
  • Young Adult

Substances

  • Gonadotropin-Releasing Hormone
  • Leuprolide